Form 4: Traws Pharma Director Awarded Equity Compensation

Traws Pharma, Inc. Director Mary Teresa Shoemaker received an award of 6,157 restricted stock units and 24,629 stock options.

Summary

• Mary Teresa Shoemaker, a Director of Traws Pharma, Inc. (TRAW), was granted equity awards on December 12, 2025.
• The awards include 6,157 restricted stock units (RSUs) which will vest 100% on December 12, 2026, converting into common stock on a one-for-one basis.
• Additionally, 24,629 stock options were granted with an exercise price of $2.33 per share.
• These stock options will vest 100% on December 12, 2026, and have an expiration date of December 12, 2035.
• Following these transactions, Mary Teresa Shoemaker directly beneficially owns 6,292 shares of common stock and 24,629 stock options.

Sentiment

Score: 7

Explanation: The equity awards granted to a director are a standard form of compensation that aligns management's interests with shareholders, generally viewed positively as it incentivizes long-term performance.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests with those of the company's shareholders, promoting long-term value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

This filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

The granting of equity awards to directors is a common practice across various industries, particularly in the pharmaceutical and biotechnology sectors, to incentivize long-term commitment and performance.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially fostering decisions that enhance long-term shareholder value.

Next Steps

• The restricted stock units are expected to convert into common stock on December 12, 2026, upon vesting.
• The stock options will become exercisable on December 12, 2026, and can be exercised until their expiration on December 12, 2035.

Key Dates

Recommendation

This Form 4 reports routine equity compensation for a director, which is a standard practice to align interests. It does not provide new information significant enough to alter an investment recommendation based solely on this filing.

Keywords

Traws Pharma, TRAW, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership